Related Experiment Video
Updated: Mar 15, 2026
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
miR-223 increases gallbladder cancer cell sensitivity to docetaxel by downregulating STMN1
Wei Lu1,2, Yunping Hu2, Qiang Ma2
1Department of General Surgery, Xinhua Hospital, Affiliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Background:
MicroRNAs (miRs) are involved in cancer carcinogenesis, and certain regulatory miRs could provide promising therapeutic methods for refractory malignancies, such as gallbladder cancer (GBC). miR-223 was found to play a pivotal role in enhancing chemotherapeutic effects, therefore evoking interest in the role of miR-223 in GBC.
Results:
miR-223 was decreased in GBC tissues and cell lines, and ectopic miR- 223 expression exhibited multiple anti-tumorigenic effects in GBC cells, including decreased proliferation, migration and invasion in vitro. However, treatment with a miR-223 inhibitor increased cell viability. We determined that STMN1 was negatively correlated with and regulated by miR-223 in GBC. miR-223 increased GBC sensitivity to docetaxel in vitro and in vivo, and the induced sensitivity to docetaxel was suppressed by the restoration of STMN1 expression.
Methods:
We examined miR-223 expression in GBC tissue and GBC cell lines using qRT-PCR. The effects of modulated miR-223 expression in GBC cells were assayed using Cell Counting Kit-8 (CCK8), flow cytometry, and wound-healing and invasion assays. Susceptibility to docetaxel was evaluated in miR-223/STMN1-modulated GBC cells and xenograft tumor models. The protein expression of relevant genes was examined by Western blotting.
Conclusions:
These findings indicated that miR-223 might serve as an onco-suppressor that enhances susceptibility to docetaxel by downregulating STMN1 in GBC, highlighting its promising therapeutic value.
Insights
MicroRNA-223 acts as an onco-suppressor in gallbladder cancer (GBC). Upregulating miR-223 enhances docetaxel chemotherapy effectiveness by targeting STMN1, offering a potential new therapy for GBC.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- MicroRNAs (miRs) play crucial roles in cancer development.
- Specific miRs are being investigated as potential therapies for difficult-to-treat cancers like gallbladder cancer (GBC).
- miR-223 has shown promise in improving chemotherapy efficacy.
Purpose of the Study:
- To investigate the role of miR-223 in gallbladder cancer (GBC).
- To determine if miR-223 can enhance the effectiveness of docetaxel chemotherapy in GBC.
- To identify the molecular mechanisms underlying miR-223's function in GBC.
Main Methods:
- Quantitative real-time PCR (qRT-PCR) to measure miR-223 expression in GBC tissues and cell lines.
- Cell viability, proliferation, migration, and invasion assays (CCK8, flow cytometry, wound-healing assays) to assess anti-tumorigenic effects.
- Western blotting and in vivo xenograft models to evaluate docetaxel sensitivity and the role of STMN1.
Main Results:
- miR-223 expression was significantly decreased in GBC tissues and cell lines.
- Restoring miR-223 expression inhibited GBC cell proliferation, migration, and invasion.
- miR-223 was found to directly downregulate STMN1 expression.
- miR-223 enhanced GBC cell sensitivity to docetaxel both in vitro and in vivo.
- The tumor-suppressive effects of miR-223 were dependent on the downregulation of STMN1.
Conclusions:
- miR-223 functions as an onco-suppressor in GBC.
- Downregulation of STMN1 by miR-223 enhances sensitivity to docetaxel chemotherapy.
- miR-223 holds significant therapeutic potential for treating gallbladder cancer.
